Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials
Pooled result · ILD events, IR per 100 person-yearsResult — go to the resultIncidence rate ratio 4.49 95 % CI 1.23–13.42Authors' conclusion
In this post hoc analysis, patients with RA who received abatacept had a lower rate of ILD events, including the subgroups of older age, lower body mass index, and no smoking history, compared with placebo.
Study context
- Population
- Adult patients with rheumatoid arthritis (RA) enrolled in 10 phase 3 clinical trials10 phase 3 trials
- Participants
- 3,708 vs 999
- Comparison
- Abatacept + methotrexate (MTX) vs placebo + MTX
- Abatacept + MTXn = 3,708
- Placebo + MTXn = 999reference
- Outcome
- Crude incidence rates (IRs) per 100 person-years of ILD events (incl. acute respiratory events suggestive of pneumonitis/ILD)
Methodological detailsretrospective, pooled safety data
- Retrospective
- Pooled safety data
Pooled result
ILD events, IR per 100 person-years
Incidence rate ratio
4.49
95 % CI 1.23–13.42
By group
Placebo + MTXvs Abatacept + MTX
IRR 4.49 (95 % CI 1.23–13.42)
As reported in the abstract
Further pooled results
Interstitial lung disease (ILD) events in subgroups (age ≥ 55 years, BMI < 30 kg/m², no smoking history, no baseline DMARD other than MTX, no prior TNFi, high DAS28-CRP, RF or ACPA positivity, receiving corticosteroids)
- Significantly lower rate of ILD events with abatacept + MTX vs placebo + MTX
Original publication
Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials. Semin Arthritis Rheum. Published 16 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →